H.C. Wainwright Reiterates Buy Rating on CorMedix (CRMD)

August 14, 2026 6:50 AM EDT Send to a Friend
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $13.00 price target on CorMedix (NASDAQ: CRMD).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login